subscribeSubscribe
EU OKs paediatric use of Gilead`s Epclusa

EU OKs paediatric use of Gilead`s Epclusa
Selina McKee PHARMATIMES
01 Sep 2020
Share Share
Gilead Announces Presentation of More Than 40 Abstracts Extensive Liver Disease

Gilead Announces Presentation of More Than 40 Abstracts Extensive Liver Disease
PRESS RELEASE
25 Aug 2020
Share Share
AbbVie’s HCV treatment receives first for shorter treatment cycle

AbbVie’s HCV treatment receives first for shorter treatment cycle
B. Hargreaves IN-PHARMATECHNOLOGIST
30 Sep 2019
Share Share
FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier & Vosevi

FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier & Vosevi
FDA
29 Aug 2019
Share Share
FDA issues safety warning for newer hepatitis C drugs following patient deaths

FDA issues safety warning for newer hepatitis C drugs following patient deaths
Jacob Bell BIOPHARMADIVE
28 Aug 2019
Share Share
Particle Sciences Expands Controlled Substance Capabilities

Particle Sciences Expands Controlled Substance Capabilities
CONTRACT PHARMA
29 May 2019
Share Share
Louisiana picks Gilead to partner on `Netflix` model for hep C

Louisiana picks Gilead to partner on `Netflix` model for hep C
Eric Sagonowsky FIERCE PHARMA
27 Mar 2019
Share Share
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa®

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa®
PRESS RELEASE
08 Jan 2019
Share Share
AbbVie`s latest hep C push highlights Mavyret`s time-to-cure advantage

AbbVie`s latest hep C push highlights Mavyret`s time-to-cure advantage
Beth S Bulik FIERCE PHARMA
13 Dec 2018
Share Share
What do Martin Shkreli, Gilead and Takeda have in common?

What do Martin Shkreli, Gilead and Takeda have in common?
John Carroll ENDPTS
06 Dec 2018
Share Share